China: MOFCOM Conditionally Clears Thermo Fisher/Life

Keywords: MOFCOM, Thermo Fisher/Life

On 14 January 2014, China's Ministry of Commerce (MOFCOM) conditionally approved the US$13.6 billion acquisition of Life Technologies Corporation by Thermo Fisher Scientific Inc. One of the more complicated transactions reviewed by MOFCOM to date, the regulator's published decision reveals a highly structured and sophisticated competitive analysis bringing greater transparency to its processes and methods. Notably, the decision provides important insight into MOFCOM's use of certain economic tools and in that respect the case represents a significant development in the regulator's decisional practice.

This legal update looks at key aspects of the case.

A more expeditious review

Filed with MOFCOM by the parties on 3 July 2013, Thermo Fisher/Life was ultimately cleared subject to conditions on 14 January 2014. At just over six months (including time before MOFCOM opened its Phase I investigation), this is a markedly shorter review time than that required for MOFCOM's other recent conditional clearances which in some instances took up to a year. Indeed in this particular case, MOFCOM was very much in "sync" with the clearance decisions issued by other global regulators to whom the transaction had been notified. And it is noteworthy that both the US Federal Trade Commission and the European Commission's press releases publishing their respective clearance decisions mention collaboration with antitrust agencies in a number of jurisdictions including China.

Economics-based quantitative analysis

Turning to substance, MOFCOM initially identified no fewer than 59 relevant product markets in which the merging parties' operations overlapped. These product markets largely related to the molecular biology, protein biology and cell culture technology segments within the life science sector. With respect to these 59 product markets, MOFCOM identified global markets for only two products – Australia/ New Zealand fetal bovine sera and siRNA reagent. For the remaining products, MOFCOM took the position that the relevant geographic market was China-wide, noting that distribution practices and pricing in China differed from other countries.

A notable feature of Thermo Fisher/Life is the extent to which MOFCOM made use of and relied upon economic analysis in reaching its various conclusions – indeed somewhat unusually the decision makes clear that MOFCOM engaged third party experts in this context. As a first step, MOFCOM undertook a Herfindahl-Hirschman Index (HHI) analysis with a view to identifying product markets potentially susceptible to competition concerns. This "screening" process narrowed the candidate markets for analysis to 13 product markets where HHI levels post-transaction were above 1500 while the HHI "delta" (or change between the pre- and post-transaction position) was in excess of 100. In choosing these particular reference points, MOFCOM appears to have had regard to the US regulators' Horizontal Merger Guidelines, in which it is noted that mergers resulting in moderately concentrated markets, where the HHI is between 1500 and 2500, that involve an increase in the HHI of more than 100 points "potentially raise significant competitive concerns and often warrant scrutiny".1

Having used the HHI methodology to identify markets of possible concern, MOFCOM then analysed the potential for post-merger price increases in each of the 13 markets at issue using a margin-HHI regression methodology and the so-called "Indicative Price Rise" test. Thermo Fisher/ Life is the first case where MOFCOM has made a public reference to using such tests as measures of unilateral effects. MOFCOM's use of these tools allowed it to "predict" that the merger would result in a price rise of 5 percent or more in 12 markets and the regulator therefore conducted further in-depth analysis on these particular segments.

At this stage MOFCOM clarifies that it made further market inquiries looking at concentration levels, the availability of substitute products, barriers to entry and expansion etc. Interestingly, MOFCOM appears to rely on brand loyalty and reputational effects in its theory of harm for certain markets. Such "strategic" barriers to entry have been recognised as among the more controversial of market entry barriers, as they are often difficult to quantify. Nevertheless, other regulators also assess the relative significance of strategic barriers in their merger reviews. The UK competition authorities' Merger Assessment Guidelines explains that "strategic advantages" arise where "incumbent firms have advantages over new entrants because of their established position"2, while the US Horizontal Merger Guidelines considers reputational barriers in the context of assessing sufficiency of entry.

MOFCOM's conclusions

Following its further analysis, MOFCOM concluded that the transaction would likely have the effect of eliminating or restricting competition in a number of markets. Its conclusions are summarised below:

  • Cell culture products (including media and sera)

    • The merging parties were two of a small number of large global suppliers with a combined market share of 40-60 percent worldwide and an even higher, although unspecified, combined market share in the China market.
    • There were very high barriers to entry as the products are mostly used in developing human vaccines and medicines with customers being generally unwilling to switch suppliers due to quality and reputational considerations.
  • SSP kits

    • The market share of the merged entity would be 40-50 percent post-transaction leading potentially to substantial price increases and harm to customers.
  • SDS-PAGE protein standards

    • The combined market share of the parties would be 56 percent in the China market. While the increment is low, the transaction would result in a marked increase in concentration levels in the market.
    • The parties were close competitors.
  • siRNA reagents

    • Although the parties' market shares were low in the China market, MOFCOM identified a combined 80-90 percent global market share resulting from the parties possession of certain patents.


In common with the European Commission and other regulators, MOFCOM required Thermo Fisher to divest both its cell culture business and gene modification business. In particular, MOFCOM required the divestiture of Thermo Fisher's 51 percent shareholding in a China-based joint venture which produces calf sera. The regulator also imposed behavioural commitments:

  • For a period of 10 years, Thermo Fisher must reduce the catalogue prices of its SSP kits and SDS-PAGE protein standards sold in China by 1 percent each year without lowering discounts granted to Chinese distributors; and
  • For a period of 10 years, Thermo Fisher must supply third parties with SSP kits and SDS-PAGE protein standards under original equipment manufacturer terms or a non-exclusive licence arrangement at the option of the third party.

Concluding remarks

Overall Thermo Fisher/Life continues a trend toward a more thorough and transparent analysis by MOFCOM and is to be welcomed on that basis. The evident coordination with overseas regulators is clearly also a positive development.

Originally published 27 February 2014


1 See page 19 of the US DOJ and FTC's 2010 Horizontal Merger Guidelines at:

2 See page 60 of the Merger Assessment Guidelines at:

Learn more about our PRC offices and Antitrust & Competition practice.

Visit us at

Mayer Brown is a global legal services organization comprising legal practices that are separate entities (the Mayer Brown Practices). The Mayer Brown Practices are: Mayer Brown LLP, a limited liability partnership established in the United States; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales; Mayer Brown JSM, a Hong Kong partnership, and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.

© Copyright 2014. The Mayer Brown Practices. All rights reserved.

This article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein. Please also read the JSM legal publications Disclaimer.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Mayer Brown
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Mayer Brown
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions